罗格列酮
纳米载体
药品
聚乙二醇
药理学
聚乳酸
药物输送
炎症
医学
PEG比率
心肌梗塞
化学
糖尿病
纳米技术
内科学
材料科学
内分泌学
生物化学
经济
有机化学
聚合物
财务
作者
Giovanna Giacalone,Nicolas Tsapis,Ludivine Mousnier,Hélène Chacun,Elias Fattal
出处
期刊:Materials
[Multidisciplinary Digital Publishing Institute]
日期:2018-09-27
卷期号:11 (10): 1845-1845
被引量:33
摘要
Among cardiovascular diseases, atherosclerosis remains the first cause of death in the United States of America and Europe, as it leads to myocardial infarction or stroke. The high prevalence of heart diseases is due to the difficulty in diagnosing atherosclerosis, since it can develop for decades before symptoms occur, and to the complexity of the treatment since targets are also important components of the host defenses. The antidiabetics thiazolidinediones, among which is rosiglitazone (RSG), have demonstrated anti-atherosclerotic effect in animal models, and are therefore promising candidates for the improvement of atherosclerosis management. Nevertheless, their administration is hindered by the insurgence of severe side effects. To overcome this limitation, rosiglitazone has been encapsulated into polymeric nanoparticles, which permit efficient delivery to its nuclear target, and selective delivery to the site of action, allowing the reduction of unwanted effects. In the present work, we describe nanoparticle formulation using polylactic acid (PLA) coupled to polyethylene glycol (PEG), their characterization, and their behavior on RAW264.7 macrophages, an important target in atherosclerosis treatment. RSG nanocarriers showed no toxicity on cells at all concentrations tested, an anti-inflammatory effect in a dose-dependent manner, up to 5 times more efficient than the free molecule, and an increased RSG uptake which is consistent with the effect shown. These biodegradable nanoparticles represent a valid tool to be further investigated for the treatment of atherosclerosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI